查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088673

帕金森氏症深部腦部刺激市場：依裝置類型、目標刺激部位、植入類型、患者年齡層和最終用戶分類－2026-2032年全球市場預測

Deep Brain Stimulation in Parkinson's Disease Market by Device Type, Target Stimulation Site, Implantation Type, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，帕金森氏症深部腦部刺激 (DVT) 市場將成長至 40.2 億美元，複合年成長率為 16.15%。

主要市場統計數據
基準年 2025 14.1億美元
預計年份：2026年 16.1億美元
預測年份 2032 40.2億美元
複合年成長率 (%) 16.15%

帕金森氏症深部腦部刺激（DBS）是一種極具價值的神經調控療法，可以幫助那些藥物治療無效的運動變異、運動障礙或震顫患者。該療法擁有數十年的臨床經驗、隨機對照試驗的證據以及基於指南的患者選擇標準。常見的治療部位包括丘腦底核、蒼白球內側核以及腹側中間核（適用於以震顫為主要症狀的患者）。

市場成長勢頭得到了可靠的流行病學數據支撐。世界衛生組織（WHO）的數據顯示，帕金森氏症患者病率在過去25年中加倍，截至2019年，全球已有超過850萬人患有此病。對於DBS設備製造商而言，商機正從單一植入手術的銷售轉向整合式深部腦部刺激平台，該平台結合了定向導線、可充電植入式脈衝產生器、基於影像的規劃、遠端支援和數據驅動的程式設計工作流程。

DBS領域的變革性變化

精準標靶、分段式電極、長壽命電池、具備感測功能的脈衝產生器以及改進的影像導引手術規劃等技術正在變革腦深部刺激（DBS）領域。這些變革拓展了治療範圍，減輕了程式設計負擔，並使製造商不僅能夠在硬體本身上實現差異化，還能在臨床工作流程效率、患者耐受性和長期治療效果等方面實現差異化。

人工智慧（AI）的累積影響

人工智慧正在DBS產品開發、手術規劃和術後最佳化等各個階段創造累積價值。機器學習正被評估用於影像分割、電極定位、症狀狀態估計和參數推薦，而自適應DBS研究則利用局部場電位等神經訊號，根據患者病情變化調整刺激強度。

帕金森氏症DBS治療的關鍵區域性見解

北美地區憑藉其專業的運動障礙中心、完善的保險報銷機制、獲得FDA已通過核准的神經調控平台以及強大的臨床試驗基礎設施，仍然是DBS（深部腦刺激）技術應用的領先地區。在歐洲，強大的臨床專業知識與更嚴格的歐洲醫療設備法規（MDR）相結合，使得證據生成、安全監測和醫療技術評估成為進入國家醫療保健系統市場的關鍵環節。

按戰略經濟區分類的關鍵群體洞察

七國集團（G7）為腦深部刺激（DBS）設備製造商提供了最成熟的市場需求環境。這是因為其成員國普遍屬於老齡化社會，擁有高度專業化的醫療體系、先進的影像基礎設施、臨床試驗網路以及完善的報銷和評估體系。歐盟（EU）因其規模和監管協調性而具有重要的戰略意義，但各成員國的採購、競標和醫療技術評估流程仍影響著設備的最終應用。

主要星展銀行市場的關鍵國家/地區特定洞察

美國憑藉其受FDA監管的創新技術、廣泛的運動障礙治療網路、專業的神經外科中心以及活躍的學術臨床試驗活動，成為全球DBS商業化的基石。加拿大透過其省級醫療保健系統支持實證醫學的應用，而墨西哥和巴西的需求則集中在擁有完善的公立和私立三級醫療體系的主要都市區，這些地區能夠處理複雜的神經外科手術和術後程控。

為星展銀行產業領導者提供的實用建議

醫療設備製造商應優先考慮差異化的臨床價值。具體而言，這包括定向刺激、電池壽命、簡化的程式設計、MRI相容性、遠端支援、便利的充電功能以及對真實臨床結果的追蹤。證據包應涵蓋運動功能改善、生活品質（QOL）降低、不利事件、再次手術率降低、編程時間縮短、藥物劑量減少、患者滿意度降低以及醫療總成本降低等方面。

調查方法

本執行摘要基於對已驗證的公共證據的三角分析，包括世界衛生組織 (WHO)檢驗症流行病學數據、同行檢驗的DBS 臨床文獻、符合運動障礙協會的臨床標準、監管資訊以及來自主要醫療保健系統的公開市場准入資訊。

結論

對於藥物治療無法有效控制症狀的帕金森氏症患者，DBS 仍然是最成熟的先進治療方法之一。市場正朝著更先進的神經調控平台發展，這些平台需要更完善的影像、感測、軟體、程式設計效率以及長期療效證據。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：帕金森氏症深部腦部刺激市場：依設備類型分類

  • 植入式脈衝產生器
    • 可充電IPG
    • 不可充電式IPG
  • Leads
    • 定向引線
    • 全方位導線
  • 擴充套件
  • 外部元件

第8章：帕金森氏症深部腦部刺激市場：以標靶刺激部位分類

  • 丘腦底核
  • 內側蒼白球
  • 丘腦
  • 橋墩和橋樑核心筒

第9章：巴金森氏症深部腦部刺激市場：依植入類型分類

  • 單側DBS
  • 雙路DBS

第10章：巴金森氏症深部腦部刺激市場：依患者年齡層分類

  • 60歲以下
  • 60-75歲
  • 75歲以上

第11章：帕金森氏症深部腦部刺激市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章：巴金森氏症深部腦部刺激市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：巴金森氏症深部腦部刺激市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：巴金森氏症深部腦部刺激市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Aleva Neurotherapeutics SA
  • Alpha Omega Engineering Ltd.
  • Beijing PINS Medical Co., Ltd.
  • Boston Scientific Corporation
  • BrainsWay Ltd.
  • Deep Brain Innovations LLC
  • Functional Neuromodulation, Ltd.
  • LivaNova PLC
  • Medtronic plc
  • Neuralink Corp.
  • Neuronetics, Inc.
  • NeuroPace, Inc.
  • NeuroSigma, Inc.
  • Newronika SpA
  • PulseNeuro LLC
  • Renishaw PLC
  • Saluda Medical Pty Ltd.
  • Sapiens Neuro
  • SceneRay Corporation Ltd.
  • Shanghai Sinovation Medical Tech
  • Soterix Medical Inc.
  • St. Jude Medical, Inc.
Product Code: MRR-A339DAEFA88E

The Deep Brain Stimulation in Parkinson's Disease Market is projected to grow by USD 4.02 billion at a CAGR of 16.15% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.41 billion
Estimated Year [2026] USD 1.61 billion
Forecast Year [2032] USD 4.02 billion
CAGR (%) 16.15%

Deep brain stimulation (DBS) in Parkinson's disease is a high-value neuromodulation field serving patients with medication-refractory motor fluctuations, dyskinesia, or tremor. The therapy is supported by decades of clinical use, randomized evidence, and guideline-based patient selection, with common surgical targets including the subthalamic nucleus, globus pallidus internus, and, for tremor-dominant cases, the ventral intermediate nucleus.

Market momentum is grounded in verified epidemiology: the World Health Organization reports that Parkinson's disease prevalence has doubled over the past 25 years, with more than 8.5 million people living with the condition globally in 2019. For DBS device manufacturers, the opportunity is shifting from one-time implant sales toward integrated deep brain stimulation platforms combining directional leads, rechargeable implantable pulse generators, imaging-based planning, remote support, and data-enabled programming workflows.

Transformative Shifts in the DBS Landscape

The DBS landscape is being transformed by precision targeting, segmented electrodes, longer-life batteries, sensing-enabled pulse generators, and improved imaging-guided surgical planning. These shifts are improving therapeutic windows, reducing programming burden, and allowing manufacturers to differentiate through clinical workflow efficiency, patient durability, and long-term outcomes rather than hardware alone.

Regulatory expectations are also becoming more demanding. The U.S. FDA, the European Medical Device Regulation framework, and other major regulators increasingly emphasize post-market evidence, cybersecurity, software validation, human factors, and real-world performance. Companies that align product design with clinical usability, payer evidence, and long-term safety monitoring are better positioned in the Parkinson's disease neuromodulation market.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across DBS product development, surgical planning, and post-implant optimization. Machine learning is being evaluated for imaging segmentation, lead localization, symptom-state estimation, and parameter recommendation, while adaptive DBS research uses neural signals such as local field potentials to adjust stimulation in response to changing patient states.

The commercial impact remains evidence-dependent. AI-enabled DBS tools must demonstrate clinical validity, bias control, explainability, cybersecurity resilience, and compliance with software-as-a-medical-device requirements. Manufacturers that develop AI as a clinician-supervised decision-support layer, rather than an autonomous replacement for neurologist expertise, are most aligned with current regulatory and clinical standards.

Key Regional Insights for DBS in Parkinson's Disease

North America remains a leading region for DBS adoption because of specialized movement disorder centers, established reimbursement pathways, FDA-cleared neuromodulation platforms, and robust clinical trial infrastructure. Europe combines strong clinical expertise with the more rigorous European Medical Device Regulation, making evidence generation, vigilance, and health technology assessment essential for market access across national health systems.

Asia-Pacific is becoming a strategic growth region as Japan, South Korea, China, Australia, and India expand advanced neurology and neurosurgery capacity alongside rapidly aging populations and rising Parkinson's disease diagnosis. Latin America shows demand in Brazil, Mexico, and major urban hospital systems but faces affordability, reimbursement, and specialist-density constraints. The Middle East, particularly high-investment Gulf health systems, is expanding advanced care and tertiary neuroscience services, while Africa remains access-limited outside select tertiary centers, creating a long-term need for training, referral pathways, and cost-sensitive DBS technologies.

Key Group Insights Across Strategic Economic Blocs

The G7 represents the most mature demand environment for DBS device manufacturers because member countries generally combine aging populations, high specialist capacity, advanced imaging infrastructure, clinical trial networks, and established reimbursement evaluation systems. The European Union is strategically important due to scale and regulatory harmonization, although national purchasing, tendering, and health technology assessment processes continue to shape adoption country by country.

BRICS markets offer large patient pools and growing neurosurgical capacity, led by China, India, and Brazil, but pricing, reimbursement, and urban-rural access gaps remain decisive. ASEAN is heterogeneous, with Singapore, Thailand, and Malaysia supporting more advanced tertiary care than lower-resource markets, while capacity building remains central in several member states. The GCC is expanding premium specialty care through public investment and medical infrastructure development, while NATO is not a healthcare purchasing bloc but includes many countries with strong neuromodulation research, data-security expectations, and advanced hospital infrastructure.

Key Country Insights in Major DBS Markets

The United States anchors global DBS commercialization through FDA-regulated innovation, extensive movement disorder networks, specialized neurosurgical centers, and strong academic trial activity. Canada supports evidence-based adoption through provincial health systems, while Mexico and Brazil show concentrated demand in major metropolitan centers where private and public tertiary care can support complex neurosurgery and post-implant programming.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have established DBS expertise, although reimbursement timing, hospital procurement, and regional access differ. Russia retains specialized neurosurgical capacity but faces broader market-access complexity. In Asia-Pacific, China is scaling domestic and international neuromodulation adoption, India combines high unmet need with affordability constraints, Japan and South Korea offer technologically advanced care with strong hospital infrastructure, and Australia benefits from specialized public and private centers serving geographically dispersed patients.

Actionable Recommendations for DBS Industry Leaders

Device leaders should prioritize differentiated clinical value: directional stimulation, battery longevity, simplified programming, MRI compatibility, remote support, patient-friendly rechargeability, and real-world outcome tracking. Evidence packages should address motor improvement, quality of life, adverse events, reoperation rates, programming time, medication reduction, patient satisfaction, and total cost of care.

Commercial teams should invest in surgeon-neurologist training, center-of-excellence partnerships, referral pathway development, and payer-ready health economics. AI-enabled features should be launched with transparent validation, clinician oversight, cybersecurity controls, interoperability planning, and post-market monitoring to build trust across regulators, hospitals, clinicians, and patients.

Research Methodology

This executive summary is based on triangulation of verified public evidence, including World Health Organization Parkinson's disease epidemiology, peer-reviewed DBS clinical literature, Movement Disorder Society-aligned practice standards, regulator communications, and publicly available market-access information from major healthcare systems.

The analysis emphasizes evidence-backed drivers rather than speculative market sizing. Regional, group, and country insights were assessed through disease burden, aging demographics, neurosurgical capacity, reimbursement maturity, regulatory requirements, technology readiness, clinical infrastructure, and observed adoption patterns in advanced movement disorder care.

Conclusion

DBS remains one of the most established advanced therapies for appropriately selected Parkinson's disease patients whose symptoms are not adequately controlled with medication. The market is moving toward precision neuromodulation platforms supported by better imaging, sensing, software, programming efficiency, and long-term evidence.

Manufacturers that combine clinically meaningful innovation with regulatory discipline, payer evidence, cybersecurity readiness, and scalable training infrastructure will be best positioned as Parkinson's disease prevalence rises and health systems demand measurable outcomes from high-cost implantable therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Deep Brain Stimulation in Parkinson's Disease Market, by Device Type

  • 7.1. Implantable Pulse Generators
    • 7.1.1. Rechargeable IPGs
    • 7.1.2. Non-rechargeable IPGs
  • 7.2. Leads
    • 7.2.1. Directional Leads
    • 7.2.2. Omnidirectional Leads
  • 7.3. Extension Kits
  • 7.4. External Components

8. Deep Brain Stimulation in Parkinson's Disease Market, by Target Stimulation Site

  • 8.1. Subthalamic Nucle
  • 8.2. Globus Pallidus Internus
  • 8.3. Thalamus
  • 8.4. Pedunculopontine Nucleus

9. Deep Brain Stimulation in Parkinson's Disease Market, by Implantation Type

  • 9.1. Unilateral DBS
  • 9.2. Bilateral DBS

10. Deep Brain Stimulation in Parkinson's Disease Market, by Patient Age Group

  • 10.1. Less than 60 years
  • 10.2. 60-75 years
  • 10.3. Greater than 75 years

11. Deep Brain Stimulation in Parkinson's Disease Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Deep Brain Stimulation in Parkinson's Disease Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Deep Brain Stimulation in Parkinson's Disease Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Deep Brain Stimulation in Parkinson's Disease Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Aleva Neurotherapeutics SA
  • 16.3. Alpha Omega Engineering Ltd.
  • 16.4. Beijing PINS Medical Co., Ltd.
  • 16.5. Boston Scientific Corporation
  • 16.6. BrainsWay Ltd.
  • 16.7. Deep Brain Innovations LLC
  • 16.8. Functional Neuromodulation, Ltd.
  • 16.9. LivaNova PLC
  • 16.10. Medtronic plc
  • 16.11. Neuralink Corp.
  • 16.12. Neuronetics, Inc.
  • 16.13. NeuroPace, Inc.
  • 16.14. NeuroSigma, Inc.
  • 16.15. Newronika S.p.A.
  • 16.16. PulseNeuro LLC
  • 16.17. Renishaw PLC
  • 16.18. Saluda Medical Pty Ltd.
  • 16.19. Sapiens Neuro
  • 16.20. SceneRay Corporation Ltd.
  • 16.21. Shanghai Sinovation Medical Tech
  • 16.22. Soterix Medical Inc.
  • 16.23. St. Jude Medical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE PULSE GENERATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE PULSE GENERATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE PULSE GENERATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RECHARGEABLE IPGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RECHARGEABLE IPGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RECHARGEABLE IPGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-RECHARGEABLE IPGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-RECHARGEABLE IPGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-RECHARGEABLE IPGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LEADS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LEADS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LEADS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIRECTIONAL LEADS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIRECTIONAL LEADS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIRECTIONAL LEADS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OMNIDIRECTIONAL LEADS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OMNIDIRECTIONAL LEADS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OMNIDIRECTIONAL LEADS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EXTENSION KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EXTENSION KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EXTENSION KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EXTERNAL COMPONENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EXTERNAL COMPONENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EXTERNAL COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SUBTHALAMIC NUCLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SUBTHALAMIC NUCLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SUBTHALAMIC NUCLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLOBUS PALLIDUS INTERNUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GLOBUS PALLIDUS INTERNUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLOBUS PALLIDUS INTERNUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THALAMUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THALAMUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THALAMUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEDUNCULOPONTINE NUCLEUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEDUNCULOPONTINE NUCLEUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEDUNCULOPONTINE NUCLEUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UNILATERAL DBS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UNILATERAL DBS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UNILATERAL DBS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BILATERAL DBS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BILATERAL DBS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BILATERAL DBS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LESS THAN 60 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LESS THAN 60 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LESS THAN 60 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL 60-75 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL 60-75 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL 60-75 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GREATER THAN 75 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GREATER THAN 75 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GREATER THAN 75 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 128. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 129. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 130. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 152. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 153. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 160. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 161. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 162. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. CANADA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. CANADA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. CANADA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 177. CANADA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 178. CANADA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 179. CANADA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. CANADA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. CANADA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MEXICO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. MEXICO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MEXICO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 185. MEXICO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 186. MEXICO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 187. MEXICO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. MEXICO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. MEXICO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 193. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 194. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 195. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GERMANY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. GERMANY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GERMANY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 209. GERMANY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 210. GERMANY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 211. GERMANY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. GERMANY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GERMANY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. FRANCE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. FRANCE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. FRANCE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 217. FRANCE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 218. FRANCE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 219. FRANCE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. FRANCE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. FRANCE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 225. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 226. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 227. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. ITALY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. ITALY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. ITALY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 233. ITALY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 234. ITALY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 235. ITALY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ITALY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ITALY DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. SPAIN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. SPAIN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. SPAIN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 241. SPAIN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 242. SPAIN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 243. SPAIN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. SPAIN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. SPAIN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. INDIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. INDIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. INDIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 257. INDIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 258. INDIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 259. INDIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. INDIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. INDIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. JAPAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. JAPAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. JAPAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 265. JAPAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 266. JAPAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 267. JAPAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. JAPAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. JAPAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 273. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 274. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 275. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 281. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 282. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
  • TABLE 283. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)